Can it make me white again? A case report of 88% phenol as a depigmenting agent in vitiligo

Farhan Mahmood¹ and Renée A Beach²

Abstract
Vitiligo is the most common depigmenting disorder. However, therapies prove to be time-consuming, costly, or slow to show efficacy. Here, we present a case of a 74-year-old female with vitiligo who underwent full-body depigmentation treatment 50 years ago. Brown patches of repigmentation appeared on the patient’s face and arms and were eventually treated with 88% phenol. Patient was later switched to compounded 3% glutathione cream for a more sustained effect. Phenol was an accessible, economical, and easily administrable therapeutic option that can result in short-term depigmentation.

Keywords
Case report, vitiligo, 88% phenol, depigmentation therapy, depigmentation agents

Introduction
Vitiligo is the most common depigmenting disorder, affecting up to 1% of the world’s population.¹ This acquired autoimmune disorder typically presents as white patches with distinct margins. Different subtypes of vitiligo such as generalized, acrofacial, and universalis may be widely distributed on the body, recalcitrant to therapy, and cosmetically disfiguring.¹,² Depigmenting therapies are employed in cases of diffuse, but incomplete, vitiligo to help standardize appearance by whitening patches of residual pigmented skin. Common depigmenting therapies include monobenzone ethyl ester of hydroquinone (MBEH), laser resurfacing, and even cryotherapy.¹,²,³ However, these therapies prove to be costly and painful when used over a large body surface area (BSA).³ Phenol in 88% concentration is an effective, seldom reported depigmenting agent for residual pigmentation in patients with vitiligo. There are reports of its use in South America and Asia to treat vitiligo,⁴,⁵ though there are no reports from North America. We present a case of partially repigmented vitiligo, which was treated with 88% phenol for depigmentation. This therapy is an accessible, economical, and easily administered option that induces short-term depigmentation.

Case report
A 74-year-old, white-appearing, ethnically Indian female presented to the dermatologist with concern over herpigmentation change. She had been diagnosed with vitiligo in her third decade of life and its extent led to treatment with benoquin for full-body depigmentation in South Africa. The depigmentation therapy resulted in uniformly white skin for the next 50 years. In 2019, the patient noted brown patches of repigmentation and became extremely distressed, prompting her to seek dermatologic attention. At consultation, the patient displayed brown macules encompassing ~10% BSA with adjacent patches of depigmentation involving the face and arms. She expressed psychological trauma due to the unexpected repigmentation. Commercially available camouflage therapies were discussed; however, the patient sought a more enduring prescription therapy.

Therapeutic depigmentation with topical MBEH then benoquin (4 months each) were attempted, followed by three sessions of cryotherapy without clinical success. Laser therapy with q-switched ruby or alexandrite lasers were considered, but the patient was unable to afford these or acquire it on a compassionate basis.

After a review of the academic literature and consulting with a local compounding pharmacy, topical application of

¹Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
²Faculty of Medicine, Division of Dermatology, Women’s College Hospital, University of Toronto, ON, Canada

Corresponding Author:
Farhan Mahmood, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8L1, Canada.
Email: fmahm059@uottawa.ca

Creative Commons Non Commercial CC BY-NC
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
88% phenol was enlisted as therapy. The patient’s face was triple-rinsed with isopropyl alcohol, then phenol solution was applied with a cotton-tipped applicator to areas of brown repigmentation. The compound exhibited a frosted appearance and was washed off in-clinic with syndet cleanser and water (Figure 1). To mitigate irritation, therapy with desonide cream was used nightly for 1 week. She reported effective depigmentation lasting 2 weeks after each application. Scheduled applications were interrupted due to the COVID-19 pandemic but resumed and were generally repeated in-office monthly. Serial photography revealed modest improvement of the skin over the face (Figure 2), which the patient initially deemed cosmetically acceptable. Ultimately, phenol therapy was discontinued after three sessions because the patient sought therapy that would provide more sustained depigmentation results. She was prescribed compounded 3% glutathione cream for daily use with reassessment planned for 3 months.

**Discussion**

This elderly female with severe repigmenting vitiligo underwent serial 88% phenol treatments for depigmentation of residual pigmented skin with good therapeutic tolerance and reasonable, but unsustained, clinical efficacy.

Phenol passively absorbs into the skin due to its lipophilic properties and interferes with melanogenesis, incapacitating melanocytes from adequately synthesizing melanin, and induces epidermal protein coagulation. In facial peels, phenol induces epidermal regeneration by forming adnexal keratinocyte and elastic fibres and increasing diameters of dermal collagen.

In clinical practice, 88% phenol is highly accessible and economically advantageous compared to MBEH, a commonly used topical depigmenting agent. This compound is easily accessed and costs around CDN$35 for 100 mL. In comparison, the estimated cost for the same volume of compounded MBEH 20% is around CDN$200. Furthermore, therapy with ruby laser costs approximately CDN$200 for every 2–3 laser pulses, with each pulse depigmenting around 1.5 cm of skin.

In addition to its affordability and accessibility, 88% phenol has previously been used as a depigmenting agent with minimal complications and reasonable results. Zanini presented a 62-year-old female with generalized vitiligo, and residual normochromic patches in the anterior cervical region lasting 8 years. The patient was treated with 88% phenol for two sessions, 45 days apart, which eliminated the residual pigmented skin. Depigmentation persisted after an 18-month follow-up without significant complications.

Kavossi also described a 13-year-old male with a 5-year history of vitiligo with macules and normally pigmented skin on the right periorbital area. Eventually, co-therapy of phenol 88% and liquid nitrogen cryotherapy led to complete depigmentation of the patient’s macules in 6 months without further complications. Cryotherapy (liquid N₂) is a cost-effective therapy that can induce rapid permanent depigmentation in vitiligo over a limited area at a time without requiring anaesthesia. Its use in combination with 88% phenol is likely to be efficient, effective, and accessible with minimal immediate complications of edema, pain, and bulla formation.

Although topical phenol is well tolerated in vitiligo, systemic ingestion of phenol between 8 and 15 g has been shown to result in a range of morbidities including cardiac arrhythmia, respiratory failure, clonic convulsions, organ failure, and even death. In clinic, 88% phenol concentration can be applied to the skin in small volumes and areas (e.g. 5 mL; ~20% of the face-neck region), at 4- to 6-week intervals for an extended duration. This protocol prevents the occurrence of serious complications. After application of 88% phenol, an antibiotic ointment and low-potency topical steroid along with sunscreen can be applied to help limit inflammation and dyspigmentation due to ultraviolet radiation (UVR) exposure.
Paradoxically, phenol itself can have a counter-effect and may induce pigmentation in vitiligo, likely due to UVR-induced melanocyte activation, melanogenesis at the basal layer, and/or post-inflammatory hyperpigmentation. This action may have occurred in this patient towards the end of her interval, just before phenol reapplications.

Our patient also presented with psychological trauma due to unexpected repigmentation after previously having ‘lived life as a white woman’. Psychological disorders occur in 75% of patients with vitiligo, most prevalently depression, due to perceived cosmetic disfigurement, unpredictable disease clinical course, and lack of predictably effective treatments. Psychological stressors, mood disturbances, self-perceived stigmatization, low self-esteem, self-image, and self-worth are also strongly associated with vitiligo. Female sex and cultures with negative connotations towards vitiligo are strong intersectional factors; the appearance of vitiligo can threaten one’s ethnic and cultural identities.

Phenol is a potential depigmenting therapy due to its availability, affordability, and ease of application. However, 88% phenol may not produce a sustained effect and may warrant co-therapy with liquid nitrogen or adjuvant topical therapy, similar to this case. As an under-utilized therapy in North America, its application deserves consideration and can help reduce repigmented vitiligo.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
Informed consent was obtained from the patient.

References
1. Ezzedine K, Eleftheriadou V, Whitton M, et al. Vitiligo. Lancet 2015; 386(9998): 74–84.
2. Mohammad TF, Al-Jamal M, Hamzavi IH, et al. Vitiligo working group. J Am Acad Dermatol 2017; 76(5): 879–888.
3. AlGhamdi KM and Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol 2011; 25(7): 749–757.
4. Zanini M. Depigmentation therapy for generalized vitiligo with topical 88% phenol solution. Anais Brasileiros De Dermatologia 2005; 80: 415–416.
5. Kavuossi H. Induction of depigmentation in a universal vitiligo patient with combination of cryotherapy and phenol. J Pakistan Assoc Dermatol 2009; 19: 112–114.
6. Stuzin JM, Baker TJ and Gordon HL. Treatment of photoaging: facial chemical peeling (phenol and trichloroaceticacid) and dermabrasion. Clin Plast Surg 1993; 20(1): 9–25.
7. Gupta D, Kumari R and Thappa DM. Depigmentation therapies in vitiligo. Indian J Dermatol 2012; 78: 49–58.
8. Rendon MJ, Berson DS, Cohen JL, et al. Evidence and considerations in the application of chemical peels in skin disorders and aesthetic resurfacing. J Clin Aesthet Dermatol 2010; 3(7): 32–43.
9. Schürer NY and Wiest L. Chemical peel anweisungen für die Praxis [Chemical peels]. Hautarzt 2006; 57(1): 61–77.
10. Babich H and Davis DL. Phenol: a review of environmental and health risks. Regul Toxicol Pharmacol 1981; 1(1): 90–109.
11. Bruce RM, Santodonato J and Neal MW. Summary review of the health effects associated with phenol. Toxicol Ind Health 1987; 3(4): 535–568.
12. Mysore V. Use of phenol to induce pigmentation in vitiligo. J Cosmet Dermatol 2002; 1(2): 99–100.
13. Landau M. Chemical peels. Clin Derm 2008; 26: 200–208.
14. Simons RE, Zevy DL and Jafferany M. Psychodermatology of vitiligo: psychological impact and consequences. Dermatol Ther 2020; 33(3): e13418.